WealthTrust Axiom’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

WealthTrust Axiom’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-333	Closed	-$1.81K	–	262
2022 Q4	$1.81K	Hold	333	–	–	﹤0.01%	248
2022 Q3	$2K	Hold	333	–	–	﹤0.01%	247
2022 Q2	$4K	Hold	333	–	–	﹤0.01%	248
2022 Q1	$8K	Hold	333	–	–	﹤0.01%	267
2021 Q4	$15K	Hold	333	–	–	﹤0.01%	265
2021 Q3	$30K	Buy	+333	New	+$34.5K	0.01%	251

Other funds holding KRBP

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WealthTrust Axiom's KRBP Position: Q1 2023 in Review

WealthTrust Axiom sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q1 2023, closing a stake of 333 shares — an estimated $1.81K sold.

WealthTrust Axiom first reported a position in KRBP in Q3 2021 and held it in 6 quarters. The position peaked at $30K in Q3 2021. 7 funds tracked by Wall St. Rank hold KRBP as of Q1 2023.

WealthTrust Axiom reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
WealthTrust Axiom sold 333 Kiromic BioPharma, Inc. Common Stock shares in Q1 2023, an estimated $1.81K.
WealthTrust Axiom first reported a position in Kiromic BioPharma, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
WealthTrust Axiom's Kiromic BioPharma, Inc. Common Stock position peaked at $30K in Q3 2021.
7 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q1 2023.

Based on WealthTrust Axiom's 13F filing for Q1 2023, filed 3 May 2023.